Pharma Sector Q1 Results Preview - On A Strong Footing: ICICI Securities

ICICI Securities Report

Pharma companies under our coverage are likely to report revenue/Ebitda/profit after tax growth of 15%/33%/28% YoY in Q1 FY24E.

The growth is likely to be led by new launches, market share expansion in key products and acquisition in U.S. and India. Aggregate gross margin to improve marginally QoQ (+250 basis points YoY) at 64.8% as higher raw material cost and mandated price cut in India may offset the benefit of better margins from niche U.S. launches.

However, operating leverage may drive a 90 bps QoQ (+300 bps YoY) surge in Ebitda margin to 22.4%. Aggregate profit after tax is expected to surge 28% YoY to Rs 86.6 billion.

Cipla Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Ajanta Pharma Ltd. and Abbott India Ltd. are our top picks in pharma space.

Key risks:

Adverse outcome of U.S. Food and Drug Administration inspections, currency volatility and inclusion of more products under National List of Essential Medicine in India.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.